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Bernt Johan von Scholten1*, Frederik Persson1, Maria S. Svane2, Tine W. Hansen1, Sten Madsbad2
and Peter Rossing1,3,4
Abstract
Background: When patients experience large weight loss, muscle mass may be affected followed by changes in
plasma creatinine (pCr). The MDRD and CKD-EPI equations for estimated GFR (eGFR) include pCr. We hypothesised
that a large weight loss reduces muscle mass and pCr causing increase in eGFR (creatinine-based equations),
whereas measured GFR (mGFR) and cystatin C-based eGFR would be unaffected if adjusted for body surface area.
Methods: Prospective, intervention study including 19 patients. All attended a baseline visit before gastric bypass
surgery followed by a visit six months post-surgery. mGFR was assessed during four hours plasma 51Cr-EDTA
clearance. GFR was estimated by four equations (MDRD, CKD-EPI-pCr, CKD-EPI-cysC and CKD-EPI-pCr-cysC).
DXA-scans were performed at baseline and six months post-surgery to measure changes in lean limb mass, as a
surrogate for muscle mass.
Results: Patients were (mean ± SD) 40.0 ± 9.3 years, 14 (74%) were female and 5 (26%) had type 2 diabetes,
baseline weight was 128 ± 19 kg, body mass index 41 ± 6 kg/m2 and absolute mGFR 122 ± 24 ml/min. Six months
post-surgery weight loss was 27 (95% CI: 23; 30) kg, mGFR decreased by 9 (−17; −2) from 122 ± 24 to 113 ± 21 ml/
min (p = 0.024), but corrected for current body surface area (BSA) mGFR was unchanged by 2 (−5; 9) ml/min/1.
73 m2 (p = 0.52). CKD-EPI-pCr increased by 12 (6; 17) and MDRD by 13 (8; 18) (p < 0.001 for both), while CKD-EPI-
cysC was unchanged by 2 (−8; 4) ml/min/1.73 m2 (p = 0.51). Lean limb mass was reduced by 3.5 (−4.4;−2.6; p < 0.
001) kg and change in lean limb mass correlated with change in plasma creatinine (R2 = 0.28, p = 0.032).
Conclusions: Major weight reductions are associated with a reduction in absolute mGFR, which may reflect
resolution of glomerular hyperfiltration, while mGFR adjusted for body surface area was unchanged. Estimates of
GFR based on creatinine overestimate renal function likely due to changes in muscle mass, whereas cystatin C
based estimates are unaffected.
Trial registration: ClinicalTrials.gov, NCT02138565. Date of registration: March 24, 2014.
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Background
Accurate assessment of glomerular filtration rate (GFR) is
important, both to evaluate the progression of renal dis-
ease, and to monitor the effect of intervention on kidney
function as well as to inform drug dosing and patient
counselling. However, optimal methods of measuring
kidney function in the setting of obesity or longitudinally
in the setting of weight change are uncertain.
Plasma creatinine is frequently used to estimate GFR,
since it has proven to be an inexpensive and reliable
index of kidney function. The primary determinant of
creatinine generation/production is skeletal muscle mass
where the final catabolite of muscular energetic metabol-
ism is creatinine [1]. Hence, if body weight - and muscle
mass in particular - changes over time and leads to
changes in plasma creatinine, this may affect estimates
of kidney function, without actual changes in accurately
measured GFR. Whether these factors impact eGFR
could depend on the equations applied, as the 4-variable
Modification of Diet in Renal Disease (MDRD) [2] and
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Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) [3] equations include plasma creatinine and
would not be affected body weight changes alone. Cysta-
tin C is a filtration marker that is less influenced by
changes in muscle mass and may be a more suitable
marker of renal function in subjects experiencing fast
and large weight reductions [4]. In this prospective inter-
vention study, we investigated the effect of a large
weight loss (after Roux-en-Y gastric bypass surgery
(RYGB)) on measured GFR (mGFR) (51Cr-EDTA plasma
clearance) and on estimated GFR (using both plasma
creatinine and cystatin C). Dual energy X-ray absorpti-
ometry (DXA)-scans were performed before and after
RYGB to estimate changes in skeletal muscle mass.
We hypothesised that a large weight loss reduces
muscle mass (lean limb mass) and plasma creatinine
leading to increases in eGFR (creatinine-based equa-
tions), whereas mGFR and cystatin C-based eGFR would
be unaffected when adjusted for the change in body sur-
face area (BSA).
Methods
Participants and study design
This prospective, open-label intervention study included
23 obese patients all scheduled for RYGB at Hvidovre
University Hospital, Denmark. Three patients never had
the surgery performed and one patient declined to par-
ticipate in the post-surgery visit. Therefore, a total of 19
patients completed the study. Type 2 diabetes was diag-
nosed according to the WHO criteria.
Patients were recruited from March 2014 and the
study was completed in June 2016.
The study design is illustrated in Fig. 1. Patients
attended the baseline visit within two weeks prior to the
scheduled RYGB and the follow-up visit was performed
six months (±2 weeks) after RYGB.
The study protocol was approved by the regional eth-
ics committee and was conducted according to the Dec-
laration of Helsinki. All patients gave written informed
consent before any study procedure was initiated. The
study is registered at ClinicalTrials.gov with identifier
NCT02138565. The two study-related visits were con-
ducted at Steno Diabetes Center, Gentofte, Denmark, and
the RYGB was performed at Hvidovre University Hospital,
Hvidovre, Denmark as described previously [5].
The primary aim was to assess the effect of a large
weight reduction on measured GFR (51Cr-EDTA plasma
clearance) and on estimated GFR (applying different
equations based on plasma creatinine or cystatin C).
Secondly, we assessed the effect on body composition
(determined by DXA-scan) in order to relate these
changes with changes in renal outcome measures.
Outcome measurements
Renal function (mGFR) and extracellular volume were
assessed during four hours measurement of plasma
51Cr-EDTA clearance by standard methods [6]. 51Cr-
EDTA was performed within two weeks prior to RYGB
and six months (± two weeks) after surgery.
For the present study, mGFR was represented by two
approaches: 1) Absolute mGFR, where mGFR was pre-
sented as the raw mGFR (ml/min) and 2) mGFR cor-
rected for concurrent body surface area (BSA): BSA-
corrected mGFR (ml/min/1.73 m2).
For the estimation of BSA we used the Du Bois & Du
Bois formula [7].
IDMS-traceable plasma creatinine was analysed using
the enzymatic Creatinine Plus method (Vitros 5600, Or-
tho Clinical Diagnostics, Illkirch Cedex, France). Stan-
dardized plasma cystatin C was analyzed on the Cobas
8000® (Roche Diagnostics, Indianapolis, IN).
Estimated GFR was calculated by four equations:
1) Creatinine equation (MDRD 1999): MDRD eGFR
[2]; 2) Creatinine equation (CKD-EPI 2009): CKD-
EPI-pCr eGFR [3]; 3) Cystatin C equation (CKD-EPI
2012): CKD-EPI-cysC eGFR [8]; and 4) Creatinine-
cystatin C equation (CKD-EPI 2012): CKD-EPI-pCr-
cysC eGFR [8].
Fig. 1 Study design
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DXA measurements of body composition were per-
formed in all patients at baseline and six months after
surgery using a Hologic Discovery A, series 82800-A
(Hologic, Bedford, MA, USA).
The following parameters were obtained: Lean body
mass (in kg), lean limb mass (in kg), fat mass (in kg)
and fat mass (in percent). Lean limb mass is consid-
ered the best surrogate measure of skeletal muscle
mass and was calculated as the total non-bone and
non-fat lean mass of the extremities: Lean mass of
left arm + lean mass of right arm + lean mass left leg
+ lean mass of right leg [9].
Urinary albumin-to-creatinine ratio (UACR) was cal-
culated as the geometric mean of three consecutive
morning spot urine samples performed at baseline and
six months after surgery.
Twenty-four-hour blood pressure was performed at
baseline and six months after surgery using BPro
(HealthStats, Singapore), a watch-like device that cap-
tures radial pulse wave reflection and calculates bra-
chial 24–h BP. BPro has been validated in people
with diabetes and meets the European Society of
Hypertension and Association for the Advancement
of Medical Instrumentation standards [10, 11]. Mean
of systolic and diastolic blood pressure and heart rate
was calculated using all readings during the 24 h.
Only 24-h blood pressure recordings with ≥ 20 read-
ings during daytime and ≥ 7 during night-time were
used for analysis. One recording was incomplete and
was discarded for the analysis.
The urinary albumin concentration of the morning
spot samples was analysed using a turbidimetric
immunoassay (Vitros 5600, Ortho Clinical Diagnostics,
Illkirch Cedex, France).
Statistical analysis
Outcome measures are presented as mean (SD) and
skewed data (UACR) are shown as geometric mean
(IQR), and analysed after log-transformation.
The change in outcome measures was analysed from
levels at baseline to six months after surgery and com-
pared using the paired samples t-tests.
Associations between changes in outcome mea-
sures were assessed by linear regression models. The
proportion of the variability explained by the models
is presented as the R2. Due to the exploratory nature
of the study, no power calculation was performed,
however based on a previous related study, we
anticipated that a total of 20 subjects would be suffi-
cient [12].
Two-sided p-values < 0.05 were considered statistical
significant. Statistical analysis was performed using IBM
SPSS 23.0 (IBM Amonk NY, USA).
Results
Baseline demographics
Patients were (mean ± SD) 40 ± 9 years, 14 (74%) were
female and 5 (26%) had type 2 diabetes. Baseline weight
was 128 ± 19 kg, body mass index 41 ± 6 kg/m2, absolute
mGFR 122 ± 24 ml/min and CKD-EPI-pCr eGFR 93 ±
18 ml/min/1.73 m2. Six patients received antihyperten-
sive treatment at baseline and no changes were pre-
scribed during the course of the study.
Renal outcome measures
Six months after RYGB, absolute GFR was reduced by
mean 9 (95% confidence interval: 2; 17; p = 0.021) ml/min,
while BSA-corrected GFR was unchanged by 2 (−5; 9; p =
0.52) ml/min/1.73 m2 (Table 1).
Plasma creatinine was reduced by 9 (5; 14; p < 0.001)
μmol/l, and plasma cystatin C was unchanged by 0.02
(−0.04; 0.07; p = 0.61) six months after RYGB. MDRD
eGFR increased by 13 (8; 18; p < 0.001) ml/min/1.73 m2,
CKD-EPI-pCr eGFR increased by 12 (6; 17; p < 0.001)
ml/min/1.73 m2, and CKD-EPI-pCr-cysC eGFR was un-
changed by 5 (−0.5; 10; p = 0.074) ml/min/1.73 m2.
CKD-EPI-cysC eGFR was unchanged by 2 (−8; 4; p =
0.51) ml/min/1.73 m2. Plasma urea was reduced by 0.7
(−1.3; −0.02; p = 0.043) mmol/l and UACR was reduced
by 23 (−35; −9; p = 0.005) %, while extracellular volume
was unchanged (p = 0.99) (Table 1).
Weight loss and body composition outcome measures
Six months after RYGB weight was reduced by mean 27
(23; 30; p < 0.001) kg or 21 (18; 24; p < 0.001) % and
body mass index was reduced by 8 (−10; −7; p < 0.001)
kg/m2. Lean limb mass was reduced by 3.5 kg (−4.4;
−2.6; p < 0.001) kg, lean body mass was reduced by 6.5
(−7.9; −5.0; p < 0.001) kg, and fat mass was reduced by
20 (−23; −18; p < 0.001) kg (Table 2).
Linear correlations
At baseline, BSA-corrected mGFR correlated significantly
with plasma creatinine and with all estimates of GFR
(R2 ≥ 0.25, p ≤ 0.029), except for MDRD (p = 0.093). After
RYGB, BSA-corrected mGFR correlated with plasma cre-
atinine and all estimates of GFR (R2 ≥ 0.34, p ≤ 0.011).
Change in BSA-corrected mGFR correlated with change
in plasma creatinine and MDRD eGFR (R2 = 0.24, p ≤
0.048) and not with changes in other renal measures.
Lean limb mass correlated significantly with plasma cre-
atinine at baseline (R2 = 0.28, p = 0.025) and after RYGB
(R2 = 0.37, p = 0.010). Change in lean limb mass correlated
with change in plasma creatinine (R2 = 0.28, p = 0.032) and
with change in UACR (R2 = 0.28, p = 0.034).
Lean body mass correlated significantly with plasma
creatinine at baseline (R2 = 0.32, p = 0.012) and after
RYGB (R2 = 0.42, p = 0.004). Change in lean body mass
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correlated with change in UACR (R2 = 0.38, p = 0.011),
and not with change in plasma creatinine or other renal
measures (p ≥ 0.38).
Discussion
In this prospective intervention study investigating the
effects of a fast and large (mean 27 kg) weight loss, ob-
tained by Roux-en-Y gastric bypass surgery, we found a
reduction in absolute mGFR, while BSA-corrected
mGFR was unchanged. Plasma creatinine was reduced
causing increases in creatinine-based eGFR (MDRD and
CKD-EPI), while cystatin C-based eGFR was unchanged
(all adjusted for BSA). Lean limb mass, a surrogate
measure of skeletal muscle mass, was reduced by mean
3.5 kg and might explain the reduction in plasma cre-
atinine, since we found a significant correlation between
these changes.
Monitoring GFR is important for diagnosis and moni-
toring of patients with kidney disease. Furthermore, it is
often used for dosage of drugs, mainly for safety reasons.
Numerous equations based on plasma creatinine have
been suggested for estimation of GFR and when com-
pared to accurately measured GFR, particularly MDRD
and CKD-EPI have been proven to be reliable. Of note,
creatinine-based eGFR equations have not been vali-
dated in morbidly obese adults or in patients with
change in body composition after RYGB [13]. Cystatin C
is less affected by muscle mass and diet than is creatin-
ine, while reports have found an association between
cystatin C concentrations and body weight and fat mass
[14–17]. In our study, cystatin C levels tended to be as-
sociated with body weight, but were not associated with
fat mass, fat percent or body mass index (data not
shown). Nonetheless, it has been anticipated that cysta-
tin C would provide a more accurate estimate of GFR
than creatinine [18]. Measuring GFR by inulin-clearance
[19], chromium-EDTA clearance [6] or iohexol clearance
[20] is considered the “gold standard” of GFR. However,
it is expensive and time consuming (usually a four hour
examination), and therefore not realistic as a routine
measurement in clinical practice or in large-scale stud-
ies. Whether mGFR should be presented absolute or
Table 1 Renal outcome measures
Variable Baseline 6 months post-surgery Change from baseline (95% CI) p-value
mGFR (51Cr-EDTA), ml/min (absolute) 122 (24) 113 (21) −9 (−17; −2) 0.021
mGFR (51Cr-EDTA), ml/min/1.73 m2 (corrected for body surface area) 88 (17) 90 (16) 2 (−5; 9) 0.52
Body surface area, m2 2.38 (0.22) 2.14 (0.23) 0.24 (0.20; 0.28) <0.001
Plasma creatinine, μmol/l 76 (18) 66 (12) −9 (−14; −5) <0.001
Plasma cystatin C, mg/l 0.94 (0.19) 0.96 (0.19) 0.02 (−0.04; 0.07) 0.61
CKD-EPI-sCr eGFR, ml/min/1.73 m2 93 (18) 105 (15) 12 (6; 17) <0.001
MDRD eGFR, ml/min/1.73 m2 84 (21) 97 (22) 13 (8; 18) <0.001
CKD-EPI-cysC eGFR, ml/min/1.73 m2 89 (19) 87 (23) −2 (−8; 4) 0.51
CKD-EPI-sCr-cysC eGFR, ml/min/1.73 m2 91 (19) 96 (21) 5 (−3; 10) 0.074
24-h systolic blood pressure, mmHg 122 (14) 124 (13) 2 (−5; 10) 0.56
24-h diastolic blood pressure, mmHg 82 (10) 79 (11) −3 (−9; 4) 0.41
Urinary albumin-to-creatinine ratio, mg/g 6.3 (2.7–8.1) 4.8 (2.1–5.2) −23 (−35; −9) % 0.005
Extracellular volume, l 20.4 (5.9) 20.4 (6.3) 0 (−2.5; 2.6) 0.99
Plasma urea, mmol/l 5.0 (1.5) 4.3 (1.1) −0.7 (−1.3; −0.02) 0.043
Plasma calcium, mmol/l 1.28 (0.04) 1.28 (0.03) 0 (−0.02; 0.02) 0.74
Values represent mean (SD) or geometric mean (IQR)
GFR glomerular filtration rate
Table 2 DXA outcome measures
Variable Baseline 6 months post-surgery Change from baseline (95% CI) p-value
Lean body mass, kg 66.2 (12.2) 59.7 (13.0) −6.5 (−7.9; −5.0) <0.001
Lean body mass + bone mineral content, kg 69.1 (12.4) 62.6 (13.3) −6.5 (−7.9; −5.0) <0.001
Lean limb mass, kg 30.6 (6.5) 27.1 (6.6) −3.5 (−4.4; −2.6) <0.001
Fat mass, kg 59.0 (12.0) 38.5 (9.9) −20.4 (−23.1; −17.7) <0.001
Fat mass, % 46.1 (5.8) 38.1 (6.2) −7.9 (−9.1; −6.7) <0.001
Weight, kg 128 (19) 101 (18) −27 (−30; −23) <0.001
Values represent mean (SD)
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BSA-corrected (expressed as per 1.73 m2) in the setting of
obesity is still unclear and may depend on the situation
[13]. However, studies have indeed questioned the use of
BSA-correction and concluded that data obtained for GFR
indexed by BSA should either be avoided or interpreted
with caution, especially in obese subjects [21, 22]. Due to
the limitations of BSA-correction, the extracellular vol-
ume has been proposed as a better parameter for body
size adjustment of GFR than BSA [23]. In our study, the
extracellular volume was essentially unchanged six
months after RYGB, hence mGFR adjusted for extracellu-
lar volume was reduced. However GFR indexed with
extracellular volume is currently not recommended [24].
Taken together, the optimal methods of measuring kidney
function in obese subjects and after weight changes are de-
bated but still indeterminate. The purpose of the present
study was to obtain a better understanding of how a large
weight loss influence measured and estimated kidney func-
tion. The study hypothesis was that change in creatinine-
based eGFR would be different than change in mGFR, since
a large weight reduction would lead to a reduction in muscle
mass affecting plasma creatinine levels without impacting
BSA-corrected mGFR. Our primary findings were that abso-
lute mGFR was reduced, BSA-corrected mGFR and cystatin
C-based eGFR were unchanged, while creatinine-based
eGFR was increased after a weight reduction of mean 27 kg.
By applying robust methods for determination of body com-
position, we were able to demonstrate that changes in
muscle mass correlated with changes in plasma creatinine.
This suggests that for monitoring changes in renal function
over time in patients experiencing a large weight loss, cysta-
tin C-based estimates of GFR may be more useful.
Other studies have demonstrated similar results. In a
study of 37 patients, a weight loss of 37 kg six months
after surgery was associated with a significant reduction
in mean creatinine, and accordingly an increase in
MDRD, while Cockcroft Gault eGFR (including both
creatinine and body weight) was decreased [25]. A small
prospective study demonstrated that BSA-corrected
mGFR, determined using clearance of iothalamate, was
reduced in a cohort of 11 women during the first year
after bariatric surgery. Notably, serum creatinine and
creatinine-based eGFR did not identify this change in
renal function, which was explained by a large reduction
in creatinine production. Preoperatively, the CKD-EPI
equation underestimated mGFR; postoperatively, mGFR
was overestimated due to the reduction in body weight
and muscle mass [12]. Of note, these studies did not
measure actual changes in body composition. In a recent
pooled analysis including more than 5000 patients, we
assessed whether a pharmaceutically induced weight loss
was associated with changes in plasma creatinine. We
demonstrated that a “stable” weight reduction of mean
1.9 kg was not associated with a change in plasma
creatinine and concluded, that in patients experiencing a
smaller weight reduction, creatinine-based equations
(MDRD and CKD-EPI) are unaffected and can be ap-
plied [26]. The extent and rate of a weight reduction as-
sociated with enough impact on skeletal muscle mass
reduction to affect levels of creatinine and eGFR is cur-
rently unknown and cannot be determined by the
present study. Depending on the magnitude of the
weight reductions, a non-creatinine-based equation (e.g.
cystatin C) should be considered for these studies, in
order to obtain reliable estimates of kidney function.
Our present study expands on previous studies investi-
gating the effects of bariatric surgery on mGFR. In studies
examining mGFR in patients with normal or supranormal
kidney function, absolute mGFR decreased significantly,
while the BSA-corrected mGFR was unchanged one year
after surgery [13, 27]. In the present study, we can confirm
these findings and in a sub-analysis of subjects with hyper-
filtration (baseline mGFR > 130 ml/min, n = 5) mGFR was
significantly reduced by 24 ml/min (data not shown). This
illustrates that the GFR-lowering effect of bariatric surgery
is more pronounced in subjects with supranormal baseline
levels of mGFR. It has been suggested that the decrease in
the absolute mGFR is a resolution of glomerular hyperfil-
tration which may result in decreased intraglomerular
pressure and kidney injury [13, 27, 28].
In a recent study, including 985 patients treated with
bariatric surgery and 985 matched controls, it was con-
cluded that patients undergoing bariatric surgery had a
58% lower risk of an eGFR decline ≥ 30% and a 57%
lower risk of doubling of serum creatinine or developing
end-stage renal disease compared with the controls. Of
note, end-stage renal disease occurred in only eight sur-
gery and ten non-surgery patients, indicating that the
vast majority of the kidney outcomes were based on
levels of creatinine [29]. While the study was well-
designed and provided valuable information with im-
portant clinical implications, a major limitation is the
use of a creatinine-based eGFR for determination of kid-
ney outcomes, as also highlighted by the authors them-
selves. In our study, plasma creatinine was reduced in all
patients except two, likely explained by a reduction in
muscle mass. We found absolute mGFR and creatinine-
based eGFR to change in opposite directions after
RYGB. In order to resolve whether bariatric surgery is
reducing the risk of adverse kidney outcomes, cystatin
C-based eGFR may be a more suitable measure.
Strengths and limitations
Strengths of this study include the prospective design
and the use of robust methods to determine changes in
renal function and body composition after RYGB. Limi-
tations include the small sample size and lack of a non-
surgical control group with a comparable weight
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reduction. As a result, we are unable to rule out that our
findings are not specifically caused by the RYGB-related
changes in the renal outcome measures.
Conclusions
Major weight reductions are associated with a reduction in
absolute mGFR, which may reflect resolution of glomerular
hyperfiltration, while mGFR adjusted for body surface area
was unchanged. Estimates of GFR based on plasma creatin-
ine overestimate renal function likely due to changes in
muscle mass, whereas cystatin C based estimates are un-
affected. Our results have important implications for both
clinicians and researchers and provide a better understand-
ing of the physiology of glomerular filtration rate and
emphasize the limitations of using plasma creatinine in the
setting of obesity and following weight changes.
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